Series A start up responsible for advising on investor relations, finance, marketing, and operations

• Led the $153M Series C executed in July 2021 including generation of >$270M in demand• Restructured finance team in preparation for transition from private to public company, achieved SOX404 compliance• Led the implementation of portfolio prioritization methodology, yielded adjustments to clinical development strategy

• Led the $146M IPO executed in April 2019, the largest pre-clinical Biotech IPO of the year • Represented company at over 15 health care conferences including corporate presentation and investor engagements • Raised over $200M including $110M Series B, $40M Convertible Note, and $30M Line of Credit Facility • Grew the finance, operations, and IT teams from 4 employees to 35. Development of teams yielded 12 employee promotions and resulted in successful transition from private to public company • Responsible for $26M, 53K square feet of expansion over 3 sites all on time and on budget

Deal finance lead in R&D World Wide Business Development for six executed deals including• Business acquisition of BMS HIV portfolio for up to $1.4B in total consideration + royalties• Divestment of ofatumumab autoimmune indications to Novartis for up to $1B + royalties• In-license/option cell and gene therapy deal with Miltenyi Biotech• In-license/option cell and gene therapy deal with Adaptimmune• In-licensed technology deal with Palantir Deals total ~£700M+ in upfront payments, ~£2.2B+ in development/sales milestones, and royalties on net sales. Also Deal Finance Lead for non-executed VC backed spin-out of 4 rare disease assets.

• Led a global team of 4 (2 Directors - US, 2 Managers - UK) responsible for investment analytics/decision making support for senior management & product development teams. • Key contributor to valuation of GSK R&D pipeline including negotiation with UK/US Tax authorities on approach; resulted in 2.5% reduction in overall GSK effective corporate tax rate• Overall Annual Portfolio Investment Board planning lead including development of key analytics used to optimize ROI for R&D on ~£1B in external spend• Business liaison member on Pipeline Progression Team presenting key results on PH IIIB/IV, long range forecast and candidate selection quality. Resulted in implementation of initiatives to improve pipeline sustainability and delivery.

• Led the formation of the Global MedImmune Capital Finance Group (1 Sr. Manager, 1 Sr. Accountant) responsible for >$200M in annual capital spend across R&D, Manufacturing, and Commercial • Published guidelines and accounting policies for MedImmune Capital Investment Life Cycle Management initiative• Presented business case analysis/justification for significant capital investments ultimately approved by senior leadership• Achieved MET level agreement of long range operating plan through development of portfolio prioritization scoring system/analytics• Capital SAP lead for Investment Management & Project Systems integration into AstraZeneca North American Platform

Portfolio Analytics lead responsible for development of analytics used to optimize investments in R&D. • Presented key pipeline results to MET through development of revenue and cost analytics for the long range operating plan. • Led the development of portfolio optimization analytics to prioritize biologic programs given a set of business constraints; rankings of small molecules and biologics achieved through financial/technical harmonization of AZ & MedI programs• Achieved consensus on MedI-545 global forecast through two-day summit with AZ country presidents in London

Responsible for P&L management of FluMist Franchise (Sales of ~$150M/Year) including S&M costs (~$20M/Year). Led hiring/development of one Sr. Analyst. • Next generation FluMist program (Quadrivalent Flu Vaccine) approved through key decision tree analytics/simulations presented to CEO. • Responsible for long range operating plan, forecasts, and accounting treatment (including gross to net) of FluMist Brand and Sales Organization• Responsible for financial/strategic/accounting input on FluMist Ex-US team• Led the close process and variance analysis for FluMist and various Sales Departments• Developed/integrated accounting policy and transaction process to support sublicense/license use of Reverse Genetics Technology with Sanofi, GSK, Novartis and CSL.

Led a team of 4 (Sr. Analyst, Two Accountants, Payroll Clerk) responsible for specialty chemicals manufacturing site delivering ~$200M per year in sales. • Part of M&A transition team which resulted in the £410M sale of Uniqema to Croda Chemicals• Led the negotiation and completion of new $8M service level agreement with SPI Polyols and FujiFilm• Led documentation introduction and implementation for finance/accounting processes; SOX Unit Champion for site• Led the consolidation, headcount reduction, capability improvement of Atlas Point Finance Function• Developed new standard costing tools for $90 mm batch process; yielding on-going conversion savings of ~$4.0 mm/yr• Improved salvage and discard management performance; yielding $1 mm reduction in discarded material• Plant Finance Stream Leader for $3.5 mm SAP implementation project• Represented Atlas Point in the monthly review of manufacturing financial performance to Uniqema executive team